The FDA has approved tavapadon (JUVMO, AbbVie) tablets for adults with Parkinson’s disease (PD), the first and only selective D1/D5 receptor agonist approved for this indication. The approval was based on data from three pivotal phase 3 studies in the TEMPO clinical trial program. As reported by Medscape Medical News, …
Read More
FDA Approves First-In-Class Med for Parkinson’s Disease
